Psychometric Properties of a Generic, Patient-Centred Palliative Care Outcome Measure of Symptom Burden for People with Progressive Long Term Neurological Conditions

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2016 Oct 26

PMID 27780237

Citations 8

Authors

Wei Gao

Vincent Crosby

Andrew Wilcock

Rachael Burman

Eli Silber

Nilay Hepgul

K Ray Chaudhuri

Irene J Higginson

Affiliations

Soon will be listed here.

Abstract

Background: There is no standard palliative care outcome measure for people with progressive long term neurological conditions (LTNC). This study aims to determine the psychometric properties of a new 8-item palliative care outcome scale of symptom burden (IPOS Neuro-S8) in this population.

Data And Methods: Data were merged from a Phase II palliative care intervention study in multiple sclerosis (MS) and a longitudinal observational study in idiopathic Parkinson's disease (IPD), multiple system atrophy (MSA) and progressive supranuclear palsy (PSP). The IPOS Neuro-S8 was assessed for its data quality, score distribution, ceiling and floor effects, reliability, factor structure, convergent and discriminant validity, concurrent validity with generic (Palliative care Outcome Scale) and condition specific measures (Multiple Sclerosis Impact Scale; Non-motor Symptoms Questionnaire; Parkinson's Disease Questionnaire), responsiveness and minimally clinically important difference.

Results: Of the 134 participants, MS patients had a mean Extended Disability Status Scale score 7.8 (SD = 1.0), patients with an IPD, MSA or PSP were in Hoehn & Yahr stage 3-5. The IPOS Neuro-S8 had high data quality (2% missing), mean score 8 (SD = 5; range 0-32), no ceiling effects, borderline floor effects, good internal consistency (Cronbach's α = 0.7) and moderate test-retest reliability (intraclass coefficient = 0.6). The results supported a moderately correlated two-factor structure (Pearson's r = 0.5). It was moderately correlated with generic and condition specific measures (Pearson's r: 0.5-0.6). There was some evidence for discriminant validity in IPD, MSA and PSP (p = 0.020), and for good responsiveness and longitudinal construct validity.

Conclusions: IPOS Neuro-S8 shows acceptable to promising psychometric properties in common forms of progressive LTNCs. Future work needs to confirm these findings with larger samples and its usefulness in wider disease groups.

Citing Articles

[Palliative neurology].

Amadori K, Steiner T Anaesthesiologie. 2024; 73(11):781-790.

PMID: 39453489 DOI: 10.1007/s00101-024-01476-4.

[Palliative neurology].

Amadori K, Steiner T Nervenarzt. 2024; 95(8):743-753.

PMID: 39023548 DOI: 10.1007/s00115-024-01701-w.

Parkinson's disease and Covid-19: Is there an impact of ethnicity and the need for palliative care.

Rukavina K, McConvey V, Chaudhuri K, Miyasaki J Int Rev Neurobiol. 2022; 165:229-249.

PMID: 36208902 PMC: 9042419. DOI: 10.1016/bs.irn.2022.03.004.

Communication, Coordination, and Security for People with Multiple Sclerosis (COCOS-MS): a randomised phase II clinical trial protocol.

Golla H, Dillen K, Hellmich M, Dojan T, Ungeheuer S, Schmalz P BMJ Open. 2022; 12(1):e049300.

PMID: 35078833 PMC: 8796263. DOI: 10.1136/bmjopen-2021-049300.

Palliative Care Intervention Trials for Adults Living With Progressive Central Nervous System Diseases and Their Caregivers: A Systematic Review.

Leeper H, Cooper D, Armstrong T J Pain Symptom Manage. 2021; 63(1):e88-e110.

PMID: 34147576 PMC: 8683574. DOI: 10.1016/j.jpainsymman.2021.06.010.

References

Aaronson N, Alonso J, Burnam A, Lohr K, Patrick D, Perrin E . Assessing health status and quality-of-life instruments: attributes and review criteria. Qual Life Res. 2002; 11(3):193-205. DOI: 10.1023/a:1015291021312. View

Revicki D, Hays R, Cella D, Sloan J . Recommended methods for determining responsiveness and minimally important differences for patient-reported outcomes. J Clin Epidemiol. 2008; 61(2):102-9. DOI: 10.1016/j.jclinepi.2007.03.012. View

HOEHN M, Yahr M . Parkinsonism: onset, progression and mortality. Neurology. 1967; 17(5):427-42. DOI: 10.1212/wnl.17.5.427. View

Jordhoy M, Kaasa S, Fayers P, Ovreness T, Underland G, Ahlner-Elmqvist M . Challenges in palliative care research; recruitment, attrition and compliance: experience from a randomized controlled trial. Palliat Med. 2000; 13(4):299-310. DOI: 10.1191/026921699668963873. View

Chahine L, Malik B, Davis M . Palliative care needs of patients with neurologic or neurosurgical conditions. Eur J Neurol. 2008; 15(12):1265-72. DOI: 10.1111/j.1468-1331.2008.02319.x. View

Sleeman K, Higginson I . A psychometric validation of two brief measures to assess palliative need in patients severely affected by multiple sclerosis. J Pain Symptom Manage. 2012; 46(3):406-12. DOI: 10.1016/j.jpainsymman.2012.08.007. View

Kurtzke J . Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 1983; 33(11):1444-52. DOI: 10.1212/wnl.33.11.1444. View

Saleem T, Higginson I, Chaudhuri K, Martin A, Burman R, Leigh P . Symptom prevalence, severity and palliative care needs assessment using the Palliative Outcome Scale: a cross-sectional study of patients with Parkinson's disease and related neurological conditions. Palliat Med. 2012; 27(8):722-31. DOI: 10.1177/0269216312465783. View

Hobart J, Lamping D, Fitzpatrick R, Riazi A, Thompson A . The Multiple Sclerosis Impact Scale (MSIS-29): a new patient-based outcome measure. Brain. 2001; 124(Pt 5):962-73. DOI: 10.1093/brain/124.5.962. View

10.

Higginson I, Costantini M, Silber E, Burman R, Edmonds P . Evaluation of a new model of short-term palliative care for people severely affected with multiple sclerosis: a randomised fast-track trial to test timing of referral and how long the effect is maintained. Postgrad Med J. 2011; 87(1033):769-75. DOI: 10.1136/postgradmedj-2011-130290. View

11.

Chaudhuri K, Martinez-Martin P, Schapira A, Stocchi F, Sethi K, Odin P . International multicenter pilot study of the first comprehensive self-completed nonmotor symptoms questionnaire for Parkinson's disease: the NMSQuest study. Mov Disord. 2006; 21(7):916-23. DOI: 10.1002/mds.20844. View

12.

Terwee C, Bot S, de Boer M, van der Windt D, Knol D, Dekker J . Quality criteria were proposed for measurement properties of health status questionnaires. J Clin Epidemiol. 2006; 60(1):34-42. DOI: 10.1016/j.jclinepi.2006.03.012. View

13.

Bausewein C, Le Grice C, Simon S, Higginson I . The use of two common palliative outcome measures in clinical care and research: a systematic review of POS and STAS. Palliat Med. 2011; 25(4):304-13. DOI: 10.1177/0269216310395984. View

14.

Norman G, Sloan J, Wyrwich K . Interpretation of changes in health-related quality of life: the remarkable universality of half a standard deviation. Med Care. 2003; 41(5):582-92. DOI: 10.1097/01.MLR.0000062554.74615.4C. View

15.

Selby J, Beal A, Frank L . The Patient-Centered Outcomes Research Institute (PCORI) national priorities for research and initial research agenda. JAMA. 2012; 307(15):1583-4. DOI: 10.1001/jama.2012.500. View

16.

Tavakol M, Dennick R . Making sense of Cronbach's alpha. Int J Med Educ. 2016; 2:53-55. PMC: 4205511. DOI: 10.5116/ijme.4dfb.8dfd. View

17.

Wyrwich K, Wolinsky F . Identifying meaningful intra-individual change standards for health-related quality of life measures. J Eval Clin Pract. 2000; 6(1):39-49. DOI: 10.1046/j.1365-2753.2000.00238.x. View

18.

McHorney C, TARLOV A . Individual-patient monitoring in clinical practice: are available health status surveys adequate?. Qual Life Res. 1995; 4(4):293-307. DOI: 10.1007/BF01593882. View

19.

Higginson I, Gao W, Saleem T, Chaudhuri K, Burman R, McCrone P . Symptoms and quality of life in late stage Parkinson syndromes: a longitudinal community study of predictive factors. PLoS One. 2012; 7(11):e46327. PMC: 3492372. DOI: 10.1371/journal.pone.0046327. View

20.

Brooks R . EuroQol: the current state of play. Health Policy. 1996; 37(1):53-72. DOI: 10.1016/0168-8510(96)00822-6. View